{"id":553194,"date":"2026-07-16T19:20:41","date_gmt":"2026-07-16T19:20:41","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/553194\/"},"modified":"2026-07-16T19:20:41","modified_gmt":"2026-07-16T19:20:41","slug":"how-does-lly-stock-reach-2100","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/553194\/","title":{"rendered":"How Does LLY Stock Reach $2,100?"},"content":{"rendered":"

At $1,189, Eli Lilly (LLY)<\/a> looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on:<\/p>\n

While the world focuses on two blockbuster drugs, a different part of the business is compounding. Lilly\u2019s immunology, oncology, and neuroscience medicines collectively grew by 160% y-o-y in the latest quarter. This overlooked engine suggests a depth beyond the headline incretin story.<\/p>\n

That diversification provides a floor, but the ceiling is still set by the cardiometabolic franchise. Mounjaro and Zepbound alone contributed $6.7 billion of new growth this quarter, making revenue the dominant lever.<\/p>\n

LLY<\/p>\n

Sector
\nHealth Care<\/p>\n

Industry
\nPharmaceuticals<\/p>\n

P\/E Ratio
\n42.1<\/p>\n

P\/E Ratio 3Y Avg
\n71.1<\/p>\n

LTM* Revenue Growth
\n47%<\/p>\n

3Y Avg Revenue Growth
\n38%<\/p>\n

LTM* Net Margin
\n35%<\/p>\n

3Y Peak Net Margin
\n35%<\/p>\n

3Y Avg Net Margin
\n23%<\/p>\n

*LTM: Last Twelve Months<\/p>\n

Photo by Pexels on Pixabay
\nHow The Math Gets There<\/p>\n

Three projections drive the upside number. Revenue compounds at 30% annually over three years, intentionally below today\u2019s 47% pace, because the recent acceleration is unlikely to extrapolate cleanly over a 3-year horizon. Net margin eases from 35% to 32% as today\u2019s LTM gives back to the longer-run average. And the multiple has work to do that is not in the company\u2019s favor. LLY\u2019s P\/E already sits at 42.1x, below its 3-year average of 71.1x. The scenario trims it further to 37.4x, because a slower forward growth rate no longer supports even today\u2019s multiple.<\/p>\n

Put those three together and earnings move from $25.3B to roughly $49.9B, a 98% jump. Apply the lower multiple to that base, and the stock lands near $2,091, only 76% above today. The multiple takes its cut before the earnings work reaches the share price.<\/p>\n

Can LLY Pull That Off?<\/p>\n

A new sales channel could add unmodeled growth beyond the current drug pipeline. The company launched Lilly Employer Connect, a platform for businesses to directly offer obesity medicines. Management sees a gradual impact in late \u201926 with more opt-ins for \u201927.<\/p>\n

And What Could Break It?<\/p>\n

The primary risk surfaced on the call is not demand, but price. Management expects price to be a headwind in the low to mid-teens for the full year. This pressure suggests the most favorable part of the cycle may be passing.<\/p>\n

If You\u2019re Buying LLY At Today\u2019s Price<\/p>\n

You are paying for steady compounding, not a re-rating and not a margin miracle. The bet is that revenue keeps moving at roughly the projected pace; if it doesn\u2019t, the math has nowhere else to turn. And one cyclical asterisk: today\u2019s LTM numbers come off a peak rather than a sustainable rate. A revert toward the 3-year baseline would lower the earnings base before the rest of the math has a chance to play out.<\/p>\n

The new Lilly Employer Connect channel offers a real path to volume, but it may not fully offset the pricing headwind.<\/p>\n

Should You Invest In Eli Lilly?<\/p>\n

For a different read on LLY, see our recent piece The Wide Divide Ahead For Eli Lilly Stock<\/a>.<\/p>\n

A careful 3-year case on a single name is still a concentrated bet, as historical volatility<\/a> across past market crises shows. Investors who build analyses like this on individual positions often want the same framework running across a diversified book, partly for discipline, partly because even the cleanest single-stock thesis can break for reasons the math does not capture.<\/p>\n

If it is exposure to healthcare as a whole you want rather than this one name, a healthcare ETF like XLV<\/a> covers that single sector. Going broader than any one sector, to a quality-first mix across the whole market, is where the portfolio below comes in.<\/p>\n

The Trefis High Quality (HQ) Portfolio<\/a> combines analytical rigor with a forward-looking view across 30 stocks, with a consistent selection framework and a sizing and re-balancing discipline designed to deliver upside without the single-name risk you just read through here.<\/p>\n

By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced a benchmark that combines the three major indices \u2013 the S&P 500, S&P Mid-cap, and Russell 2000.<\/p>\n","protected":false},"excerpt":{"rendered":"At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years…\n","protected":false},"author":2,"featured_media":553195,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[44038,213837,213834,213836,213832,103,397,396,61,60,120180,77445,213833,212764,99324,213835],"class_list":["post-553194","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-abbv","tag-amgn","tag-buy-lly","tag-compare-lly-stock","tag-eli-lilly-stock","tag-health","tag-health-care","tag-healthcare","tag-ie","tag-ireland","tag-jnj","tag-lly","tag-lly-stock","tag-mrk","tag-pfe","tag-sell-lly"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/553194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=553194"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/553194\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/553195"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=553194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=553194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=553194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}